Table 2 Clinicopathological findings (n = 60).
Pt # | Gender | Age | HPV status | Staging | Site | Single CTCs | CTC clusters | # cells per cluster | Follow up FDG Pet Scan |
|---|---|---|---|---|---|---|---|---|---|
1 | f | 58 | negative | I | Oral Cavity | 0 | 0 | 0 | |
2 | m | 57 | negative | I | Oral Cavity | 1 | 0 | 0 | |
3 | m | 69 | negative | I | Oropharynx | 0 | 0 | 0 | |
4 | m | 57 | negative | I | Oral Cavity | 0 | 0 | 0 | |
5 | m | 71 | negative | I | Oral Cavity | 0 | 0 | 0 | |
6 | f | 64 | unknown | I | Oral Cavity | 0 | 0 | 0 | |
7 | m | 78 | negative | II | Larynx | 1 | 0 | 0 | |
8 | m | 55 | negative | II | Oral Cavity | 0 | 0 | 0 | |
9 | m | 62 | negative | II | Oral Cavity | 0 | 0 | 0 | |
10 | m | 59 | positive | II | Oral Cavity | 0 | 0 | 0 | |
11 | m | 77 | negative | II | Oral Cavity | 0 | 0 | 0 | |
12 | m | 64 | negative | II | Oral Cavity | 0 | 0 | 0 | |
13 | m | 56 | negative | III | Oral Cavity | 0 | 0 | 0 | |
14 | m | 55 | negative | III | Oral Cavity | 0 | 0 | 0 | |
15 | m | 69 | negative | III | Larynx | 0 | 0 | 0 | |
16 | m | 63 | negative | III | Oropharynx | 0 | 0 | 0 | |
17 | m | 63 | negative | III | Oropharynx | 0 | 0 | 0 | |
18 | m | 78 | negative | III | Oral Cavity | 0 | 0 | 0 | |
19 | m | 66 | unknown | III | Larynx | 5 | 0 | 0 | |
20 | f | 62 | positive | III | Oral Cavity | 0 | 0 | 0 | |
21 | m | 63 | unknown | III | Larynx | 0 | 0 | 0 | |
22 | m | 74 | positive | IV | Oral Cavity | 2 | 2* | 13,8 | lung lesion |
23 | m | 88 | negative | IV | Oral Cavity | 1 | 0 | 0 | lung lesion |
24 | m | 81 | positive | IV | Oropharynx | 0 | 0 | 0 | |
25 | m | 60 | Positive | IV | Oropharynx | 4 | 0 | 0 | |
26 | m | 64 | negative | IV | Oral Cavity | 4 | 1 | 6 | |
27 | m | 50 | Positive | IV | Oropharynx | 0 | 1 | 3 | |
28 | f | 65 | negative | IV | Oral Cavity | 4 | 0 | 0 | |
29 | m | 74 | positive | IV | Oropharynx | 3 | 0 | 0 | |
30 | f | 45 | positive | IV | Oropharynx | 1 | 0 | 0 | |
31 | m | 58 | Positive | IV | Oropharynx | 0 | 2 | 3,3 | |
32 | m | 73 | negative | IV | Oropharynx | 0 | 0 | 0 | |
33 | m | 73 | negative | IV | Oral Cavity | 0 | 0 | 0 | |
34 | m | 55 | positive | IV | oropharynx | 0 | 0 | 0 | |
35 | m | 56 | negative | IV | Oropharynx | 4 | 0 | 0 | |
36 | m | 69 | positive | IV | Oropharynx | 0 | 0 | 0 | |
37 | m | 62 | positive | IV | Oropharynx | 0 | 0 | 0 | |
38 | m | 58 | positive | IV | Oropharynx | 4 | 1 | 5 | lung lesion |
39 | m | 66 | positive | IV | Oropharynx | 0 | 0 | 0 | |
40 | m | 79 | positive | IV | Oropharynx | 0 | 0 | 0 | |
41 | m | 66 | negative | IV | Larynx | 4 | 2 | 8,10 | lung and liver lesions |
42 | m | 50 | positive | IV | Oral Cavity | 3 | 2 | 3,5 | |
43 | m | 75 | positive | IV | Oral Cavity | 0 | 0 | 0 | |
44 | m | 54 | positive | IV | Oropharynx | 0 | 0 | 0 | |
45 | f | 70 | positive | IV | Oropharynx | 0 | 0 | 0 | |
46 | m | 53 | negative | IV | Oropharynx | 3 | 1 | 6 | |
47 | m | 77 | negative | IV | Hypophaynx | 0 | 0 | 0 | |
48 | m | 50 | unknown | IV | Oral Cavity | 0 | 0 | 0 | |
49 | m | 65 | negative | IV | Oropharynx | 3 | 2* | 5,7 | liver lesion |
50 | m | 58 | unknown | IV | Oropharynx | 1 | 1 | 3 | |
51 | m | 74 | positive | IV | Oropharynx | 0 | 0 | 0 | |
52 | m | 62 | positive | IV | Oropharynx | 10 | 0 | 0 | |
53 | m | 23 | negative | IV | Hypopharynx | 0 | 0 | 0 | |
54 | m | 61 | positive | IV | Hypopharynx | 0 | 0 | 0 | |
55 | m | 50 | positive | IV | Oral Cavity | 0 | 1 | 3 | |
56 | f | 59 | negative | IV | Oral Cavity | 0 | 1 | 4 | |
57 | m | 59 | positive | IV | Oropharynx | 5 | 3 | 5,5,7 | lung lesion |
58 | m | 50 | positive | IV | Oropharynx | 4 | 1 | 3 | |
59 | m | 64 | positive | IV | Oropharynx | 0 | 2* | 7,5 | lung lesion |
60 | m | 60 | negative | IV | Salivary Glands | 0 | 0 | 0 |
